The incidence of autoimmune diseases, such as multiple sclerosis and type 1 diabetes, has spiked in developed countries in recent decades. In three studies published today in Nature, researchers describe the molecular pathways that can lead to autoimmune disease and identify one possible culprit that has been right under our noses — and on our tables — the entire time: salt.
To stay healthy, the human body relies on a careful balance: too little immune function and we succumb to infection, too much activity and the immune system begins to attack healthy tissue, a condition known as autoimmunity. Some forms of autoimmunity have been linked to overproduction of TH17 cells, a type of helper T cell that produces an inflammatory protein called interleukin-17.
But finding the molecular switches that cause the body to overproduce TH17 cells has been difficult, in part because conventional methods of activating native immune cells in the laboratory often harm the cells or alters the course of their development.
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
So when researchers heard a talk by Hongkun Park, a physicist at Harvard University in Cambridge, Massachusetts, about the use of silicone nanowires to disarm single genes in cells, they approached him immediately, recalls Aviv Regev, a biologist at the Massachusetts Institute of Technology (also in Cambridge) and a co-author on two of the studies.
Park showed last year that these nanowires can be used to manipulate genes in immune cells without affecting the cells’ functions. For the first of the Nature studies, Regev and her colleagues used Park's technology to piece together a functional model of how TH17 cells are controlled, she says. “Otherwise,” she says, they would have been only “guessing in the dark.”
In the second study, an affiliated team of researchers observed immune cell production over 72 hours. One protein kept cropping up as a TH17-signal: serum glucocorticoid kinase 1 (SGK1), which is known to regulate salt levels in other types of cells. The researchers found that mouse cells cultured in high-salt conditions had higher SGK1 expression and produced more TH17 cells than those grown in normal conditions.
“If you incrementally increase salt, you get generation after generation of these TH17 cells,” says study co-author Vijay Kuchroo, an immunologist at Brigham and Women’s Hospital in Boston, Massachusetts.
In the third study, researchers confirmed Kuchroo’s findings, in mouse and human cells. It was “an easy experiment — you just add salt”, says David Hafler, a neurologist at Yale University in New Haven, Connecticut, who led the research.
But could salt change the course of autoimmune disease? Both Kuchroo and Hafler found that in a mouse model of multiple sclerosis, a high-salt diet accelerated the disease’s progression.
All this evidence, Kuchroo says, “is building a very interesting hypothesis [that] salt may be one of the environmental triggers of autoimmunity”.
But Kuchroo and other researchers say that evidence so far cannot predict the effect of salt on human autoimmunity. “As a physician, I’m very cautious,” Hafler says. “Should patients go on a low-salt diet? Yes,” he says, adding that “people should probably already be on a low-salt diet” for general health concerns.
Other experts are intrigued by the findings. “They have a very clear effect in vitro,” says John O’Shea, scientific director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases Intramural Research Program in Bethesda, Maryland. But Hafler and others note that there are likely many cell types and environmental factors involved in triggering autoimmunity.
The results offer tantalizing leads for drug targets for autoimmune conditions. But O’Shea notes that it is unclear whether TH17 proliferation is a factor in all autoimmune disease. A targeted drug that might work to relieve psoriasis might not subdue rheumatoid arthritis. “When we say autoimmunity, we’re implying that it’s one thing,” O’Shea says. “But it’s not one thing — it’s heterogeneous.”
This article is reproduced with permission from the magazine Nature. The article was first published on March 6, 2013.
